The Groundbreaking AGenDA Project Led by Wits University

The Assessing Genetic Diversity in Africa (AGenDA) project, spearheaded by researchers at the University of the Witwatersrand (Wits) in Johannesburg, South Africa, marks a pivotal moment in global genomics. Published in the prestigious journal Nature in January 2026, the study introduces over 1,000 new whole-genome sequences from underrepresented African populations, significantly enriching international genetic databases. This initiative addresses a long-standing bias where the vast majority of genomic data—up to 90% in some cases—derives from individuals of European ancestry, leading to inaccurate disease risk predictions for Africans, who harbor the planet's greatest human genetic diversity.

Africa's genetic landscape is uniquely rich due to humanity's origins on the continent, with two individuals from different African regions often showing more genetic variation than a European and an Asian combined. By focusing on understudied groups, AGenDA not only corrects this Eurocentric skew but also promises to uncover millions of novel variants that could redefine precision medicine worldwide.

Leadership from Wits' Sydney Brenner Institute

At the helm is Professor Michèle Ramsay, Director of Wits' Sydney Brenner Institute for Molecular Bioscience (SBIMB), who serves as the lead author. Supported by key team members like Dr. Furahini Tluway (AGenDA Project Coordinator), Professor Scott Hazelhurst (Head of Bioinformatics), and Dr. Ananyo Choudhury (co-lead), the project exemplifies South African higher education's growing prowess in leading continent-wide research. Wits' role underscores the university's commitment to translating academic excellence into real-world impact, building on prior efforts like the Human Heredity and Health in Africa (H3Africa) Consortium and the Africa Wits-INDEPTH Partnership for Genomic Studies (AWI-Gen), which targeted cardiometabolic diseases.

This leadership positions Wits—and South African universities more broadly—as hubs for genomic innovation, fostering collaborations that empower African scientists and ensure data sovereignty.

Methodology: A Collaborative, Ethical Approach to Genome Sequencing

AGenDA involved sequencing the whole genomes of 1,217 individuals from 25 distinct ethnolinguistic groups across nine African countries: Angola, Democratic Republic of Congo, Kenya, Libya, Mauritius, Rwanda, Tunisia, Zimbabwe, and South Africa (project coordination). These included hunter-gatherers, Nilo-Saharan and Afro-Asiatic speakers, understudied Bantu subgroups, North Africans, and Indian Ocean islanders—populations sorely missing from global datasets.

The process emphasized ethical rigor: communities were engaged prior to sampling, with consent forms translated into local languages and tailored to cultural norms. Data management occurs through African-led committees, prioritizing participant rights and preventing exploitation. This co-created model, rooted in H3Africa principles, ensures equitable partnerships and high-quality, representative data.

• Step 1: Partner with local research groups for recruitment.
• Step 2: Conduct community consultations and obtain informed consent.
• Step 3: Perform whole-genome sequencing for comprehensive variant detection.
• Step 4: Analyze via bioinformatics pipelines at Wits SBIMB.
• Step 5: Share data openly via African governance structures.

Key Findings: Unlocking Millions of Novel Genetic Variants

The study has already identified patterns poised to reveal millions of previously unknown genetic variants, far exceeding expectations due to Africa's deep evolutionary history. Early analyses show substantial geographic and ethnolinguistic gaps filled, such as North African Berber groups and island populations from Mauritius.

Crucially, incorporating AGenDA data dramatically boosts polygenic risk scores (PRS)—statistical models aggregating thousands of variants to predict disease likelihood. For type 2 diabetes, PRS accuracy improved up to 10-fold in some cohorts compared to European-only models, with 2-5x gains across tested traits like coronary artery disease and breast cancer. This demonstrates how African-inclusive datasets enhance global PRS portability.

Photo by Annie Spratt on Unsplash

Transforming Precision Medicine for African Populations

Underrepresentation has real consequences: PRS derived from non-African data often fail Africans, missing risk variants or yielding false predictions. AGenDA's genomes enable tailored PRS, vital for prevalent conditions like hypertension, diabetes, and infectious diseases disproportionately affecting the continent.

In South Africa, where cardiometabolic diseases surge amid urbanization, AWI-Gen data (precursor to AGenDA) already informs local health strategies. Future applications include ancestry-aware genetic testing, drug response prediction, and pandemic preparedness—a boon for the National Health Insurance scheme.

Wits and South African Universities' Role in Genomics Capacity Building

Wits SBIMB exemplifies how South African higher education drives genomic sovereignty. Training local bioinformaticians like Prof. Hazelhurst equips the next generation, while collaborations with Stellenbosch, UCT, and international partners amplify impact.

Government support via the Department of Science and Innovation (DSI) and H3Africa funding has elevated SA universities to leaders in African genomics, attracting talent and investment. For aspiring researchers, opportunities abound in research jobs at institutions like Wits.

• South Africa's genomics output: Leads Africa with 40% of continent's publications.
• Capacity gains: Thousands trained via H3Africa initiatives.
• Economic ripple: Precision medicine market projected at R10bn+ by 2030.

Global Scientific and Ethical Implications

AGenDA's data benefits humanity: African variants, being ancestral, clarify variant functionality for all. Robust GWAS from diverse ancestries yield better therapeutics, as seen in improved PRS transferability.

Ethically, African-led governance prevents neo-colonial data extraction, setting a model for equitable global research. Prof. Ramsay notes: "AGenDA corrects the Eurocentric imbalance so genetic research works for Africans and the world."

Challenges, Solutions, and Future Outlook

Challenges persist: Funding shortages, infrastructure gaps, and ethical harmonization across borders. Solutions include sustained DSI investment, pan-African data platforms, and international partnerships.

Future: Expand to 10,000+ genomes, integrate with AI for variant prioritization, and launch Africa-specific PRS for 100+ traits. Wits plans BioHub expansions for drug discovery.

Photo by Олександр К on Unsplash

• Short-term: PRS validation trials in SA clinics.
• Medium-term: Genomic newborn screening pilots.
• Long-term: Personalized medicine mainstream in Africa by 2035.

Stakeholder Perspectives and Actionable Insights

Dr. Tluway emphasizes: "By sequencing whole genomes, we create rich data for scientists worldwide." For universities, invest in bioinformatics curricula; for policymakers, prioritize genomic infrastructure; for researchers, collaborate via academic career advice.

Rate professors like Ramsay on Rate My Professor to guide peers. Explore university jobs in genomics.

Conclusion: A New Era for African-Led Genomics

Wits' AGenDA heralds precision medicine's equitable future, empowering South African higher education and global science. Stay informed on opportunities at higher-ed-jobs, professor ratings via /rate-my-professor, and career tips at higher-ed-career-advice. Engage with the discourse—your insights matter.